Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2015—The diagnostics division of Siemens Healthcare announced the launch of three scalable hematology systems: the Advia 360 System, Advia 560 System, and Advia 560 AL System. These lower-capacity systems offer testing capabilities for small to mid-size laboratories and may also be used as backup systems for larger laboratories.
May 2015—Seegene announced that the Food and Drug Administration has granted 510(k) market clearance for its TOCE-based herpes simplex virus types 1 and 2 assay. This is the first product Seegene has taken through the FDA, and it opens the way for the company’s other planned FDA submissions of multiplex real-time PCR reagents.
May 2015—Myriad RBM launched immunoassay services based on Quanterix’s ultrasensitive Simoa (single molecule array) platform, which enables the accurate measurement of protein biomarkers that were previously difficult or even impossible to detect in blood samples.
May 2015—The diagnostics division of Siemens Healthcare announced the availability of two urine testing solutions for U.S. central laboratories—the Clinitek Novus Automated Urine Chemistry Analyzer and the Clinitek AUWi Pro Automated Urine Workstation.
May 2015—Thermo Fisher Scientific and Samsung Electronics have formed a strategic collaboration to jointly design, develop, and market new point-of-care solutions in key applications, such as the detection of sepsis, drugs of abuse, and therapeutic drug monitoring as well as the detection of cardiac problems and women’s health conditions.
May 2015—The Clinical and Laboratory Standards Institute has published a new document, “Process Management (QMS18-Ed1).” This guideline describes four requirements for managing laboratory processes and provides suggestions for effectively meeting regulatory and accreditation requirements, optimizing efficient use of resources, and contributing to patient safety and positive outcomes.
May 2015—Enzo Biochem announced the development of the FlowScript assay in detection of messenger RNA from HPV oncogenes E6 and E7. The FlowScript technology platform is a proprietary flow-cytometry-based molecular detection system for the multiplex analysis of cell function and identity; the HPV E6/E7 assay is the first product to use this novel platform. Analysis is performed on a small volume of a liquid cytology specimen and can be incorporated as a reflex test measure following abnormal Pap smear results.
May 2015—Seegene announced that Health Canada has approved its six-target Allplex Respiratory Panel 5 assay, which identifies influenza virus A and B, RSV A and B, and influenza A virus subtypes H1 and H3.
May 2015—WaveSense, a manufacturer of in vitro diagnostic cell targeting, enrichment, and isolation products for pathology, urology, and oncology, added a product to its line of cell enrichment applications delivered through its patented EpiSep medical product line.
May 2015—EKF Diagnostics has introduced the Stanbio Chemistry Glycated Serum Protein LiquiColor test, a diabetic biomarker test that provides a two- to three-week indicator of average blood glucose, closing the information gap between daily blood glucose testing and the two- to three-month HbA1c reading. GSP serves as an accurate intermediate marker of glycemia in instances where HbA1c may be of limited value, such as pregnancy, reduced RBC lifespan, and hemodialysis.
